Background. Antibody-mediated rejection (AMR) represents one of the cardinal causes of late allograft loss after kidney transplantation, and there is great need for noninvasive tools improving early diagnosis of this rejection type. One promising strategy might be the quantification of peripheral blood DNA levels of the highly prevalent and apathogenic Torque Teno virus (TTV), which might mirror the overall level of immunosuppression and thus help determine the risk of alloimmune response. Methods. To assess the association between TTV load in the peripheral blood and AMR, 715 kidney transplant recipients (median, 6.3 years posttransplantation) were subjected to a systematical cross-sectional AMR screening and, in parallel, TTV quantification. Results. Eighty-six of these recipients had donor-specific antibodies and underwent protocol biopsy, AMR-positive patients (n = 46) showed only 25% of the TTV levels measured in patients without AMR (P = 0.003). In a generalized linear model, higher TTV levels were associated with a decreased risk for AMR after adjustment for potential confounders (risk ratio 0.94 per TTV log level; 95% confidence interval 0.90-0.99; P = 0.02). Conclusions. Future studies will have to clarify whether longitudinal assessment of TTV load might predict AMR risk and help guide the type and intensity of immunosuppression to prevent antibodymediated graft injury.
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(Transplantation 2017;101: 360-367) R egistry analyses have failed to demonstrate major improvements in long-term survival of kidney allografts over the last decades, 1 and there is emerging evidence for a critical role of antibody-mediated rejection (AMR) as a major cause of chronic transplant injury and loss. 2 Besides distinct baseline immunological factors, such as recipient presensitization and levels of HLA incompatibility, insufficient levels of immunosuppression, which in some instances might be due to medication nonadherence, were shown to pose recipients at risk for the development of AMR. 3, 4 Although diagnostic criteria of this rejection type are now well established, 5 there is still a need for noninvasive screening tools to timely uncover emerging rejection processes 6 and provide a useful basis for the early implementation of therapeutic interventions.
In this respect, a promising strategy might be the monitoring of peripheral blood levels of the human apathogenic Torque Teno virus (TTV), which might mirror the overall strength of innate and specific immunity. 7, 8 TTV DNA can be detected in up to 90% of tested healthy and diseased individuals, whereby peripheral blood levels of viral load might be closely related to the immunological status of the host. 9, 10 Indeed, after organ transplantation, considerable increases in TTV DNA load were reported. 11 Longitudinal evaluation of TTV in lung transplant recipients has revealed an increase shortly after transplantation, with a peak within the first 3 months followed by a slow decrease over the following 2 years. 12, 13 Interestingly, in lung transplants, TTV load was found to associate with the type of immunosuppression, whereby patients on tacrolimus had significantly higher levels of TTV than those on cyclosporine. 12 Remarkably, in heart allograft recipients, TTV was lower in patients who experienced early organ rejection. 14 To our knowledge, there is currently no study that has systematically evaluated the relationship between TTV load and AMR occurrence after kidney transplantation. We hypothesized that, as an indicator of higher immunocompetence, low TTV DNA levels associate with a higher risk of rejection. In this study, we systematically investigated the relationship between TTV load and AMR in a large prevalent population of long-term kidney transplant recipients, who were subjected to a cross-sectional HLA antibody and AMR screening.
MATERIALS AND METHODS

Study Patients
The present study included 715 recipients of a kidney allograft. It was based on a prospective cross-sectional screening for AMR in the context of the BORTEJECT trial (www.clinicaltrials.org; NCT01873157). The design of the BORTEJECT trial has earlier been reported in detail. 15 In brief, 741 recipients were included in the cross-sectional part of the trial and subjected to Luminex-based anti-HLA antibody testing. Key inclusion criteria were a functioning graft at 6 month or longer posttransplantation and an estimated glomerular filtration rate (eGFR) greater than 20 mL/min per 1.73 m 2 . Key exclusion criteria were acute rejection less than 1 month before screening and acute deterioration of graft function suspicious of acute rejection. One hundred eleven of these recipients were donor-specific antibody (DSA)-positive and 86 of them were subjected to protocol biopsies. 16 The present study included 715 of these screened individuals. Twenty-six patients were excluded, because material for TTV testing (n = 1) or protocol biopsies (n = 25; no informed consent or 1 or more exclusion criteria that precluded inclusion in the interventional study part of the BORTEJECT trial) were not available. Complement-dependent cytotoxicity (CDC) crossmatch (XM) conversion was performed by immunoadsorption-based desensitization. 17, 18 Extended criteria donors were defined as 60 years or older, or older than 50 years with at least 2 of the following conditions: history of hypertension, serum creatinine greater than 1.5 mg/dL or cause of death resulting from a stroke. Delayed graft function was defined as requirement of more than 1 dialysis in the first week after kidney transplantation. Kidney function was assessed using eGFR according to the Modification of Diet in Renal Disease formula. 19 
HLA Antibody Characterization
As previously described in detail, 16 patient sera were in a first step prescreened for anti-HLA class I and II reactivity using LABScreen Mixed assays (One Lambda, Canoga Park, CA). HLA antibody-positive sera were then heat-inactivated to prevent the prozone effect and subjected to HLA class I and/or II single antigen bead testing (HLA class I, LABScreen Single Antigen HLA class I Antibody Detection Test Combi; HLA class II, LABScreen Single Antigen HLA class II Antibody Detection Test-Group 1; One Lambda). The presence of DSAwas determined on the basis of recorded HLA reactivity patterns assessed on single-antigen bead panels (>1000 median fluorescence intensity [MFI] was considered positive) and the results of donor/recipient HLA class I and II typing. For DSA-positive recipients, MFI levels of the peak DSA were recorded. Of the 715 kidney transplant recipients included in the analysis, 370 subjects were HLA antibody screening positive (48%), 270 were single-antigen bead assay positive (38%), and 86 had DSA and were subjected to protocol biopsy (12%).
Biopsies AMR-typical lesions, such as glomerulitis, transplant glomerulopathy, peritubular capillaritis, capillary microthrombi, intimal arteritis, and multilayering of peritubular capillary basement membranes were documented and scored following the rules of the 2013 update of the BANFF scheme. Immunohistochemical C4d staining was scored on paraffin sections whereby, according to the BANFF scheme, minimal staining (C4d1) was considered positive. 5 In addition to the 44 patients diagnosed with AMR due to acute or chronic active AMR in the BORTEJECT trial, 2 patients with chronic inactive AMR were also included in this analysis.
TTV DNA Quantification TTV DNA was extracted from 200 μL of plasma using the NucliSENS easyMAG platform (bioMerieux, France) as recommended by the manufacturer and eluted in 50 μL of elution buffer. TTV DNA was quantitated by TaqMan real time-polymerase chain reaction (PCR) as described previously. 20 The quantitative PCR reactions were performed in a volume of 25 μL using 2Â TaqMan Universal PCR Master Mix, containing 5 μL of extracted DNA, 400 nM of each primer, and 80 nM of the probe. Thermal cycling was started for 3 minutes at 50°C, followed by 10 minutes at 95°C, and then by 45 cycles at 95°C for 15 seconds, at 55°C for 30 seconds, and at 72°C for 30 seconds using the 7300 Real Time PCR System (Applied Biosystems, Foster City, CA). Results were recorded in copies/mL. TTV DNA quantitation was in the linear range from 2 to 10 log 10 copies/mL as determined by the use of 10-fold dilutions of a plasmid standard. Limit of detection was 2 log 10 copies/mL of plasma. In each run, a TTV DNA standard, a negative control (no template) and 2 positive controls (patient sera; median 5.3 log 10 copies/mL) were included. Comparing DNA loads of the positive controls between each of the 14 test runs, a median difference of 0.11 log 10 copies/mL (interquartile range [IQR], 0.04-0.19 log 10 copies/mL) was detected. Duplicates within 11 test runs showed a median DNA load difference of 0.24 log 10 copies/mL (IQR 0.03-0.36 log 10 copies/mL). None of the samples showed signs of PCR inhibition as confirmed by quantitation of known amount of control DNA spiked into the samples before DNA extraction.
Statistics
Summaries for continuous variables are presented as the median and IQR. The Mann-Whitney U test was used for comparing continuous data. Categorical variables are presented as absolute numbers and percentages, and group comparisons were made using the χ 2 or Fisher exact tests. Bivariate correlations were calculated using Spearman coefficient. Associations between TTV and AMR were initially tested applying logistic regression. We used contingency tables with a χ 2 test for hypothesis testing after categorizing TTV into quintiles. Score tests were used to assess linear trends. Logistic regression models were applied to assess whether TTV was independently associated with AMR as the outcome. TTV log level was the main covariable and other predictors of AMR and TTV were simultaneously entered as covariables: donor and recipient age, female sex, previous kidney transplantation, a positive pretransplant CDCXM, CDC panelreactivity (PRA) greater than 10%, preformed DSA, HLA mismatch in A, B, and DR, ABO incompatibility, antibody induction therapy, initial immunosuppression including tacrolimus, cyclosporine, mechanistic target of rapamycin (mTOR) inhibitor, belatacept and mycophenolic acid, immunosuppression at screening including triple immunosuppression, steroids, tacrolimus, cyclosporine and belatacept, eGFR and protein-creatinine ratio at the time of screening and years between transplantation and screening. Covariables with missing data were entered as indicator variables with "missing" as a separate category. Significance of single model parameters was assessed by the Wald test. We used the likelihood ratio test for deviation from linearity, variable contribution to the models and the investigation of interactions, respectively. For the final model, we used a generalized linear model with a log link function to directly estimate risk ratios (RR) with 95% confidence intervals (CI) including the most clinical relevant confounders of AMR (female sex, previous kidney transplantation, CDCXM conversion, CDC-PRA >10%, eGFR, and protein-creatinine ratio). We did not include pretransplant DSA, because solid phase DSA detection was not part of the clinical routine before 2009 and therefore data were only available from 264 (37%) of the patients. A 2-sided P value less than 0.05 was generally considered statistically significant. Exact tests were used where applicable. We used MS EXCEL 2010 (Redmond, WA), IBM SPSS Statistics 20.0 (SPSS Inc., Chicago, IL) and STATA 14.1 (STAT coop., College Station, TX) for data management and analysis.
RESULTS
This cross-sectional study included 715 kidney allograft recipients subjected to AMR screening after a median of 6.3 years (IQR, 2.6-12.6) posttransplantation. Forty-six (6%) of these patients were diagnosed with AMR (acute or chronic active AMR: n = 44; chronic inactive AMR: n = 2). Median time interval between transplantation and screening was 4.4 years (IQR, 1.8-12.8) in AMR+ and 6.6 years (IQR, 2.7-12.7; P = 0.19) in AMR− patients. Baseline characteristics are provided in Table 1 and Table 2 . AMR+ patients were more often female and recipients of a retransplant and were more frequently sensitized to HLA antigens before transplantation (preformed DSA, >10% CDC-PRA and/or a positive CDCXM), more often received antibody induction therapy and/or immunoadsorption-based desensitization 17, 18 and less often received mycophenolic acid. At the time of screening, AMR+ patients showed lower eGFR.
TTV Load in Relation to Baseline Characteristics
TTV DNA was detected in 678 patients (95%) with a median of 2.3 Â 10 5 copies/mL (IQR, 1.9 Â 10 4 to 1.9 Â 10 6 ). As illustrated in Figure 1 , TTV load was highest in patients screened 6 to 12 months after transplantation, with a median of 3.5 Â 10 6 copies/mL (IQR, 1. Table 3 , TTV load was higher in male subjects and recipients of an ABO-incompatible transplant and associated with older recipient age and higher HLA mismatch. In addition, TTV load was associated with higher eGFR at the time of screening (Table 4) .
TTV Load in Relation to Immunosuppressive Therapy
As shown in Table 4 , antibody induction therapy and tacrolimus-based initial immunosuppression were associated with 2-fold higher TTV levels. In contrast, TTV levels were significantly lower in patients on cyclosporine-based or mTOR inhibitor-based treatment. A remarkable finding was that initial treatment with belatacept was associated with a 45-fold increase in viral load. Analyzing immunosuppressive therapy at the time of screening, we found that patients on triple immunosuppression had 2-fold higher TTV levels compared with patients with dual immunosuppression or single therapy, and lower levels were detected in patients who were off steroids or antimetabolite. Again, tacrolimus was associated with higher and cyclosporine with lower levels of ]; P = 0.003; Figure 2A) . A robust and linear inverse association between TTV load and AMR was confirmed using score tests. Univariate logistic regression revealed a decrease in risk for AMR of 0.91 per TTV log level (95% CI, 0.87-0.96; P = 0.001). Logistic regression models demonstrated that associations between TTV load and AMR were independent of potential confounders. Similarly, also, a generalized linear model revealed an inverse independent association with TTV log level and AMR risk (RR, 0.94 per TTV log level; 95% CI, 0.90-0.99; P = 0.02; Table 5 ).
In the next step, we focused on the subgroup of 86 patients subjected to protocol biopsy on the basis of a positive DSA result. A major finding was that only 46 (53%) of these recipients were diagnosed with AMR and as many as 40 subjects (47%) did not meet the diagnostic criteria of this rejection type. Remarkably, as illustrated in Figure 2 Finally, TTV load was found to inversely correlate with MFI of peak DSA (R = −0.27; P = 0.01), a marker, which in the studied cohort was shown to associate with AMR ]; P = 0.007).
DISCUSSION
The most important finding of our study was the inverse association of TTV load in the peripheral blood of kidney transplant recipients with the occurrence of late AMR. A major strength of our study, which included a cross-sectional cohort of long-term transplant recipients subjected to a systematic rejection screening, is its large sample size, which allowed for a comprehensive multivariate analysis. Remarkably, even after adjustment for a variety of relevant confounders, TTV load remained independently associated with AMR diagnosis. Our data support the results of an earlier smaller study suggesting a relationship between viral load and transplant rejection in thoracic organ transplant recipients.
14 Within a sensitivity analysis restricted to biopsied recipients, AMR also associated with lower TTV levels in peripheral blood, providing further evidence for a role of TTV load in the detection of humoral alloresponses after kidney transplantation. Similarly, viral load inversely associated with C4d staining in peritubular capillaries, a marker that has been repeatedly shown to predict a more severe course of rejection. 21, 22 In this respect, it is important to note that TTV viral load was also associated with the fluorescence intensity of detected DSA, which might reflect the pathogenic potential of the alloresponse and predict the extent of antibody mediated graft injury. 16, 23 Prevalence of TTV in our cohort was 95% with a median TTV load of 2.3 Â 10 5 copies/mL. Although similar results were obtained in liver transplant recipients, higher TTV levels were reported for lung allograft recipients, presumably a result of higher levels of immunosuppression. 12, 13, 24 In our crosssectional analysis, we found the highest TTV levels in recipients screened after 6 to 12 months posttransplantation, with a stepwise decrease in levels at later time points. Dynamics of TTV load over time might reflect changing levels of immunosuppression. In this respect, our data are consistent with earlier studies. For example, in patients after lung transplant, peak levels of TTV were found between day 30 and 90 posttransplant with a decrease thereafter and in a cohort of patients after liver transplant including long-term data up to year 15 TTV load constantly declined over time. 12, 24 In accordance with previous studies performed in healthy individuals, 25, 26 analysis of our cohort revealed higher TTV levels in older subjects. This might be explained by immunologic senescence, with less ability of the elderly to cope with viral replication and infections. 27 Moreover, in line with earlier results obtained in nontransplant cohorts, TTV load was found to be lower in female recipients. 25, 26 In this context, a more effective adaptive immune response to viral pathogens in women was suggested, which might be promoted by estrogen. 28 In addition, higher levels were detected in patients with a high HLA mismatch. Similar associations were described in kidney transplant patients with polyoma viremia. 29 A higher HLA mismatch might lead to a reduced virus clearance by escape of virus-specific immunity due to the recipient major histocompatibility complex restriction of the T cell response. 30 A major finding was that TTV load associated with the intensity of immunosuppressive regimen at the time of transplantation and rejection screening, respectively. Recipients who had been subjected to induction and/or desensitization therapy and patients on triple immunosuppression and steroids at the time of screening showed higher levels of TTV. Similarly, higher levels were detected in recipients of an ABO-incompatible transplant, presumably an indirect consequence of intensified immunosuppression in these distinct patient cohorts. Notably, our study could not establish an association between TTV load and calcineurin inhibitor trough levels, which might be in contrast to a smaller study in lung and heart transplant patients showing a relationship between tacrolimus trough levels at early time points and a relative shift in genomic abundance within the virome toward TTV. 14 In addition, our results provide evidence that TTV load might be closely related to the type of immunosuppression. In line with a recent study performed in lung transplant FIGURE 2. TTV load in peripheral blood in relation to AMR diagnosis (A, overall cohort; B, DSA+ recipients subjected to protocol biopsy). Box plots indicate median, IQR, and range. b Protein-creatinine ratio category 0, n = 198, 36-107 mg/g; category 1, n = 204, 108-277 mg/g; category 2, n = 201; 278-1250 mg/g. recipients, we detected significantly higher TTV levels in patients on tacrolimus-based immunosuppression and lower levels in patients on cyclosporine-based immunosuppression. 12 One might speculate that these data reflect the higher immunosuppressive potential of tacrolimus as suggested by the results of large systematic intervention trials. 31 Remarkably, mTOR inhibitor-based immunosuppression was associated with comparably low TTV levels. This might be of particular interest considering the increased risk of rejection reported from mTOR inhibitor use. 32, 33 Notably, mounting evidence indicates that mTOR inhibitors might decrease the incidence of cytomegalovirus infection in solidorgan recipients 34, 35 and one might speculate that there could also be an additional direct effect of this compound on TTV replication. Interestingly, the highest levels of TTV were observed in patients on belatacept-based immunosuppression. Belatacept is well established to preserve kidney function and, as suggested by a recent analysis of longterm results of the BENEFIT trial, improve transplant survival. 36 Moreover, in support of its high immunosuppressive potential, belatacept was shown to prevent the formation of DSA, an effect that might have considerably contributed to favorable outcomes. 36 Potent suppression of immune surveillance by costimulation blockade might at least in part have contributed to a markedly enhanced TTV replication observed in our cohort. There is emerging evidence that costimulation via CD28 might be crucial for generation of antiviral T cells. 37 One might speculate that costimulation blockade might have led to insufficient formation of TTV-specific T cells and thus directly influenced viral control in patients with belatacept-based immunosuppression. Finally, a more intense immunosuppression due to an increased rate of induction therapy in the subgroup of patients treated with belatacept might have at least partly contributed to higher TTV levels.
Calcineurin inhibitor trough levels at the time of AMR screening did not associate with rejection diagnosis. We are aware that our study, which did not include details regarding cumulative dosage or longitudinal concentration measurements, was not designed to determine the predictive value of calcineurin inhibitor trough level monitoring. Likewise, the study design did not allow testing the predictive value of TTV load. However, our results might provide a valuable basis for future prospective studies designed to clarify the value of longitudinal TTV load assessment in predicting AMR occurrence. Further studies will have to assess the independent value of TTV quantification as a tool for guidance of individualized immunosuppressive treatment. Factors that would support the use of TTV detection as a monitoring tool are the high prevalence of TTV infection in human populations, as well as the noninvasive, PCR-based detection method, which allows for sufficient standardization between centers.
Our study has several limitations. First and most importantly, TTV was analyzed as a single snap shot at heterogeneous time points and data on TTV dynamics preceding AMR diagnosis are not available. Moreover, our study design does not prove a causative relationship between the intensity of immunosuppression and levels of TTV replication. Longitudinal assessment of TTV load in individual patients and prospective protocols of TTV guided immunosuppression are needed to determine whether TTV quantification has any advantage over currently available monitoring strategies. Second, we did not include screening for non-HLA antibodies and only DSA+ patients were subjected to a protocol biopsy. One might speculate that our strategy might have led to some underestimation of AMR prevalence in our cohort. Third, screening was restricted to patients with a functioning graft more than 6 months after kidney transplantation and no acute deterioration of graft function. Accordingly, we are not able to provide data on the relationship between TTV load and early rejection or rejection associated with a rapid deterioration of kidney function. Finally, our study did not establish an association between TTV load and cellular rejection. With cellular rejection being the prominent rejection type early after kidney transplantation while rarely described in late biopsies, it is not surprising that T cell-mediated rejection was diagnosed in none of our biopsied patients.
In conclusion, our data demonstrate an independent association between TTV load and late AMR in recipients of a kidney transplant. Future studies might investigate monitoring of TTV load for risk prediction of AMR and TTV guided immunosuppression to prevent antibodymediated graft injury.
